TY  - JOUR
AU  - Heiss, Wolf-Dieter
PY  - 2018
DA  - 2018/09/19
TI  - Contribution of PET Imaging to Clinical Management of Gliomas
JO  - OBM Neurobiology
SP  - 011
VL  - 02
IS  - 03
AB  - Gliomas originating from glial cells, comprise about 30 % of all primary central nervous system tumors and 80 % of malignant brain tumors. Gliomas are different with respect to their biological activity and are categorized according to grades, from benign to malignant with high recurrence rates. For diagnosis location and extent of tumor is assessed by CT and MRI, but for grading additional parameters are necessary: contrast enhanced CT and MRI reveal damage of blood brain barrier, perfusion weighted MRI shows regional blood supply and MR spectroscopy permits insight into regional metabolism. Positron emission tomography (PET) of glucose metabolism, amino acid and nucleoside uptake can assess tumor grade and invasive growth, indicates effects on function of tissue outside the tumor, demonstrates treatment efficacy, detects recurrencies and yields prognostic information.   Coregistration of PET and MRI combines the high-resolution morphologic with the biologic information. This imaging technology is optimized in hybrid MR/PET by which morphologic, functional, metabolic, and molecular information is assessed simultaneously in the human brain.
SN  - 2573-4407
UR  - https://doi.org/10.21926/obm.neurobiol.1803011
DO  - 10.21926/obm.neurobiol.1803011
ID  - Heiss2018
ER  -